SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$41.71 USD
+0.78 (1.91%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $41.73 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for SpringWorks Therapeutics falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 479 | 592 | 374 | 508 | 328 |
Receivables | 6 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 0 | 0 | 0 | 0 |
Other Current Assets | 13 | 8 | 9 | 5 | 4 |
Total Current Assets | 501 | 600 | 383 | 513 | 331 |
Net Property & Equipment | 18 | 14 | 3 | 1 | 1 |
Investments & Advances | 185 | 9 | 62 | 57 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 15 | 3 | 3 | 3 | 2 |
Total Assets | 726 | 630 | 452 | 576 | 335 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 8 | 3 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 66 | 39 | 25 | 15 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 3 | 0 | 0 | 0 |
Total Current Liabilities | 78 | 51 | 30 | 18 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 15 | 16 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 100 | 72 | 30 | 19 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,524 | 1,130 | 715 | 676 | 395 |
Retained Earnings | -895 | -570 | -293 | -119 | -73 |
Other Equity | 1 | -1 | 0 | 0 | 0 |
Treasury Stock | 4 | 1 | 0 | 0 | 0 |
Total Shareholder's Equity | 626 | 558 | 422 | 557 | 322 |
Total Liabilities & Shareholder's Equity | 726 | 630 | 452 | 576 | 335 |
Total Common Equity | 626 | 558 | 422 | 557 | 322 |
Shares Outstanding | 62.50 | 62.30 | 49.20 | 48.70 | 43.00 |
Book Value Per Share | 10.02 | 8.96 | 8.59 | 11.44 | 7.49 |
Fiscal Year End for SpringWorks Therapeutics falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 384 | 437 | 479 | 422 | 477 |
Receivables | 25 | 16 | 6 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 5 | 3 | 0 | 0 |
Other Current Assets | 15 | 14 | 13 | 10 | 7 |
Total Current Assets | 431 | 472 | 501 | 432 | 484 |
Net Property & Equipment | 18 | 18 | 18 | 21 | 18 |
Investments & Advances | 145 | 146 | 185 | 4 | 5 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 16 | 15 | 15 | 4 | 4 |
Total Assets | 617 | 657 | 726 | 468 | 517 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 7 | 7 | 6 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 46 | 56 | 66 | 40 | 35 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 5 | 4 | 3 | 2 |
Total Current Liabilities | 55 | 69 | 78 | 50 | 42 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 15 | 15 | 16 | 17 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 61 | 89 | 100 | 73 | 66 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,591 | 1,561 | 1,524 | 1,200 | 1,177 |
Retained Earnings | -1,022 | -982 | -895 | -801 | -721 |
Other Equity | -1 | 0 | 1 | 0 | 0 |
Treasury Stock | 12 | 11 | 4 | 4 | 4 |
Total Shareholder's Equity | 557 | 567 | 626 | 395 | 451 |
Total Liabilities & Shareholder's Equity | 617 | 657 | 726 | 468 | 517 |
Total Common Equity | 557 | 567 | 626 | 395 | 451 |
Shares Outstanding | 74.00 | 74.00 | 62.50 | 62.50 | 62.50 |
Book Value Per Share | 7.52 | 7.67 | 10.02 | 6.32 | 7.22 |